chrX-47846285-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_007137.5(ZNF81):c.18C>T(p.Asp6=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0099 in 1,207,438 control chromosomes in the GnomAD database, including 529 homozygotes. There are 3,971 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.014 ( 80 hom., 527 hem., cov: 23)
Exomes 𝑓: 0.0095 ( 449 hom. 3444 hem. )
Consequence
ZNF81
NM_007137.5 synonymous
NM_007137.5 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.680
Genes affected
ZNF81 (HGNC:13156): (zinc finger protein 81) This gene encodes a protein that likely functions as a transcription factor. The protein contains an N-terminal KRAB domain and several C2H2-type zinc finger motifs. Mutations in this gene cause an X-linked form of intellectual disability (MRX45). Microduplication of a region of chromosome X including this gene has also been associated with other forms of intellectual disability. [provided by RefSeq, Jul 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.75).
BP6
Variant X-47846285-C-T is Benign according to our data. Variant chrX-47846285-C-T is described in ClinVar as [Benign]. Clinvar id is 130853.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-47846285-C-T is described in Lovd as [Likely_benign].
BP7
Synonymous conserved (PhyloP=-0.68 with no splicing effect.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.152 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ZNF81 | NM_007137.5 | c.18C>T | p.Asp6= | synonymous_variant | 2/5 | ENST00000338637.13 | NP_009068.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ZNF81 | ENST00000338637.13 | c.18C>T | p.Asp6= | synonymous_variant | 2/5 | 3 | NM_007137.5 | ENSP00000341151 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0140 AC: 1571AN: 112152Hom.: 80 Cov.: 23 AF XY: 0.0154 AC XY: 527AN XY: 34308
GnomAD3 genomes
AF:
AC:
1571
AN:
112152
Hom.:
Cov.:
23
AF XY:
AC XY:
527
AN XY:
34308
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0310 AC: 5397AN: 173823Hom.: 247 AF XY: 0.0261 AC XY: 1592AN XY: 60901
GnomAD3 exomes
AF:
AC:
5397
AN:
173823
Hom.:
AF XY:
AC XY:
1592
AN XY:
60901
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00948 AC: 10382AN: 1095232Hom.: 449 Cov.: 30 AF XY: 0.00953 AC XY: 3444AN XY: 361240
GnomAD4 exome
AF:
AC:
10382
AN:
1095232
Hom.:
Cov.:
30
AF XY:
AC XY:
3444
AN XY:
361240
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0140 AC: 1567AN: 112206Hom.: 80 Cov.: 23 AF XY: 0.0153 AC XY: 527AN XY: 34372
GnomAD4 genome
AF:
AC:
1567
AN:
112206
Hom.:
Cov.:
23
AF XY:
AC XY:
527
AN XY:
34372
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:2
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 24, 2014 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 07, 2013 | - - |
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at